Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Net Cash Flow for 6 consecutive years, with -$15.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 147.75% to -$15.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Dec 2025, down 107.54% year-over-year, with the annual reading at -$3.3 million for FY2025, 107.54% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$15.3 million at Lexicon Pharmaceuticals, down from $28.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $76.3 million in Q2 2023, with the low at -$81.2 million in Q3 2023.
  • Average Net Cash Flow over 3 years is $1.4 million, with a median of -$2.4 million recorded in 2024.
  • The sharpest move saw Net Cash Flow plummeted 179.82% in 2024, then soared 2754.03% in 2025.
  • Over 3 years, Net Cash Flow stood at $1.3 million in 2023, then surged by 2279.91% to $32.1 million in 2024, then plummeted by 147.75% to -$15.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$15.3 million, $28.3 million, and -$12.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.